The JTB Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the JTB gene in the Jurkat T lymphocyte line. This model is produced by CRISPR/Cas9-mediated disruption of the endogenous JTB locus, generating a heterogeneous pool of cells with loss-of-function mutations. The polyclonal format retains genetic diversity, avoiding clonal artifacts and enabling robust population-level functional analyses. It serves as a versatile tool for studying JTB-dependent mitochondrial processes.
Jurkat cells are an immortalized human CD4+ T lymphocyte line derived from a 14-year-old male with acute lymphoblastic leukemia (ALL). As a suspension cell line, they are extensively used to model T cell receptor signaling, leukemia biology, and lymphocyte activation. Their rapid growth and well-characterized signaling pathways make them ideal for genetic manipulation, allowing investigation of JTB??s role in mitochondrial function within a malignant T cell context.
JTB encodes a MICOS complex subunit essential for mitochondrial cristae junction maintenance. It interacts with MIC60 (IMMT), MIC19 (CHCHD3), MIC25 (CHCHD6), SAM50, and MTX1. JTB is regulated by hypoxic and apoptotic stress and functions downstream of mitochondrial import machinery. Its loss disrupts cristae architecture, causing cytochrome c release, caspase activation, and mitochondrial membrane potential dissipation, while impairing oxidative phosphorylation and respiratory chain supercomplex formation. BCL2 family proteins BCL2 and BAX modulate these apoptotic outcomes.
In Jurkat cells, JTB knockout provides a model to study mitochondrial contributions to apoptotic resistance in T cell leukemia. JTB disruption sensitizes cells to intrinsic apoptosis, a pathway often dysregulated in ALL. The knockout also allows exploration of how MICOS dysfunction affects T cell receptor signaling and metabolic reprogramming. Additionally, JTB regulation by hypoxia makes this tool relevant for investigating mitochondrial adaptation in the tumor microenvironment, offering insights into leukemia pathogenesis.
Applications include Western blot analysis of MICOS subunits, immunofluorescence for mitochondrial morphology (TOM20), flow cytometry for mitochondrial membrane potential (TMRE/TMRM), cytochrome c release and caspase activity assays, Seahorse metabolic flux analysis, and co-immunoprecipitation of interacting partners. Cell viability assays following apoptotic challenges??such as staurosporine or BH3 mimetics??facilitate genetic interaction screens. For further information, please contact Ascent Research.
